- Home
- AMIX vs BGLC Comparison
AMIX vs BGLC Comparison
Compare AMIX & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMIX
- BGLC
- Stock Information
- Founded
- AMIX 2014
- BGLC 2017
- Country
- AMIX United States
- BGLC Malaysia
- Employees
- AMIX N/A
- BGLC N/A
- Industry
- AMIX
- BGLC Medical Specialities
- Sector
- AMIX
- BGLC Health Care
- Exchange
- AMIX NYSE
- BGLC Nasdaq
- Market Cap
- AMIX 7.3M
- BGLC 7.6M
- IPO Year
- AMIX N/A
- BGLC N/A
- Fundamental
- Price
- AMIX $3.46
- BGLC $0.25
- Analyst Decision
- AMIX
- BGLC
- Analyst Count
- AMIX 0
- BGLC 0
- Target Price
- AMIX N/A
- BGLC N/A
- AVG Volume (30 Days)
- AMIX 188.6K
- BGLC 1.7M
- Earning Date
- AMIX 02-11-2025
- BGLC 11-15-2024
- Dividend Yield
- AMIX N/A
- BGLC N/A
- EPS Growth
- AMIX N/A
- BGLC N/A
- EPS
- AMIX N/A
- BGLC N/A
- Revenue
- AMIX N/A
- BGLC $9,259,858.00
- Revenue This Year
- AMIX N/A
- BGLC N/A
- Revenue Next Year
- AMIX N/A
- BGLC N/A
- P/E Ratio
- AMIX N/A
- BGLC N/A
- Revenue Growth
- AMIX N/A
- BGLC N/A
- 52 Week Low
- AMIX $2.88
- BGLC $0.21
- 52 Week High
- AMIX $152.00
- BGLC $3.39
- Technical
- Relative Strength Index (RSI)
- AMIX 34.39
- BGLC 34.94
- Support Level
- AMIX $2.88
- BGLC $0.21
- Resistance Level
- AMIX $3.60
- BGLC $0.28
- Average True Range (ATR)
- AMIX 0.33
- BGLC 0.03
- MACD
- AMIX 0.22
- BGLC -0.00
- Stochastic Oscillator
- AMIX 45.90
- BGLC 11.86
About AMIX AUTONOMIX MEDICAL INC
Autonomix Medical Inc is a development-stage medical device development company focused on advancing innovative technologies for sensing and treating disorders relating to the nervous system. Its first-in-class technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies.
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.